RaQualia Pharma (TSE:4579) Long-Term Debt: 円2,011 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
59 GF Score
Price 円462.00
GF Value 円310.51
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is RaQualia Pharma Long-Term Debt?

RaQualia Pharma TSE:4579 +0.87% 59 Long-Term Debt is 円2,011 Mil as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 59/100 and a GF Value™ of 円310.51 (Significantly Overvalued). The stock has 4 warning signs investors should review.

RaQualia Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was 円2,011 Mil.

RaQualia Pharma's quarterly Long-Term Debt declined from Sep. 2025 (円2,267 Mil) to Dec. 2025 (円2,139 Mil) and declined from Dec. 2025 (円2,139 Mil) to Mar. 2026 (円2,011 Mil).

RaQualia Pharma's annual Long-Term Debt increased from Dec. 2023 (円39 Mil) to Dec. 2024 (円2,651 Mil) but then declined from Dec. 2024 (円2,651 Mil) to Dec. 2025 (円2,139 Mil).

RaQualia Pharma  (TSE:4579) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

RaQualia Pharma Long-Term Debt Related Terms

RaQualia Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Long-Term Debt Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 9.17 39.05 2,651.43 2,138.81

RaQualia Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,523.28 2,395.12 2,266.97 2,138.81 2,010.66
TSE:4579
59GF Score
RaQualia Pharma Inc TSE:4579
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円2,011 Mil mean?
RaQualia Pharma (TSE:4579) has a Long-Term Debt of 円2,011 Mil as of Mar. 2026.
Is RaQualia Pharma's Long-Term Debt too high?
RaQualia Pharma's current Long-Term Debt is 円2,011 Mil. Overall, RaQualia Pharma has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Long-Term Debt compare to VRTX and REGN?
RaQualia Pharma's Long-Term Debt of 円2,011 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. RaQualia Pharma's current Long-Term Debt is 円2,011 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Overvalued. The stock's GF Value™ is 円310.51, compared to a current price of 円462.00 — trading 48.8% above its estimated fair value. The current Long-Term Debt is 円2,011 Mil. RaQualia Pharma's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Long-Term Debt is 円2,011 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be overvalued. The current stock price of 円462.00 is trading 48.8% above its estimated GF Value™ of 円310.51. GuruFocus considers RaQualia Pharma to be Significantly Overvalued.

Key valuation signals for TSE:4579:

  • Long-Term Debt: 円2,011 Mil
  • GF Value™: 円310.51 vs. price of 円462.00 (48.8% above fair value)
  • GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
59GF Score

Get the complete analysis for TSE:4579

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円462.00
Price
円310.51
GF Value